Zepbound Side Effects

Zepbound side effects range from mild digestive discomfort to serious medical complications. The medication, generic name tirzepatide, slows stomach emptying, reduces appetite and affects blood sugar regulation. While these effects support weight loss, they can also produce unwanted reactions.

Many of the drug’s listed side effects involve the digestive system. Patients commonly report:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain

These side effects are more likely when starting treatment or increasing the dose. Reduced appetite, indigestion, heartburn and sulfur-like burps are also frequently reported.

Other documented reactions include fatigue, headache, dizziness and injection site reactions such as redness, swelling or itching. Some individuals also report muscle pain, hair loss or changes in sex drive or mental health issues.

Some reports also describe serious eye complications, including non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden vision loss.

Listed vs. potentially unlisted side effects

Drug labels are intended to warn patients and doctors about known risks, but they may not reflect the full range or severity of complications reported after widespread use. Some patients have experienced serious injuries that they allege were not adequately disclosed at the time of prescription.

Some GLP-1 medications are linked with severe gastrointestinal conditions such as gastroparesis (stomach paralysis) and ileus. Other injuries, such as blood clots and pulmonary aspiration, have also been reported. More recently, researchers confirmed a link between GLP-1 medications and vision problems.

The onset of Zepbound side effects varies widely from person to person. Some patients experience symptoms within days of their first injection, while others develop problems during the first week or after a dosage increase. Because tirzepatide slows gastric emptying and affects appetite regulation, reactions occur as the body adjusts to the medication.

Early symptoms may include nausea, reduced appetite, fatigue and general digestive discomfort. For some, these effects improve over time. However, symptoms that worsen or fail to resolve may signal a more serious complication.

Warning signs that require prompt medical attention include:

• Persistent vomiting
• Severe or worsening abdominal pain
• Inability to tolerate food or fluids
• Signs of dehydration
• Rapid, unintended weight loss

In some cases involving GLP-1 medications, complications such as gastroparesis have lasted months or longer and sometimes continued after they stopped taking the drug.

Zepbound is part of a broader class of medications used to treat obesity and type 2 diabetes, and is chemically identical to Mounjaro®.

Semaglutide medications (Ozempic®, Wegovy® and Rybelsus®) may produce similar digestive symptoms. Liraglutide (Saxenda®) typically requires daily injections and may cause nausea early in treatment.

Unlike semaglutide-based medications, Zepbound contains tirzepatide, which activates both GLP-1 and GIP receptors. This dual mechanism can produce strong metabolic effects and also affects digestive function.

Across GLP-1 and dual-agonist weight-loss drugs, patients commonly report gastrointestinal effects such as persistent nausea, vomiting, constipation or diarrhea, abdominal pain and reduced appetite.

Lawsuits involving Zepbound and similar medications are proceeding in two coordinated federal MDLs addressing different categories of alleged injuries linked to GLP-1 receptor agonist drugs. Motley Rice attorney Jonathan Orent serves as co-lead counsel for both MDL 3094 and MDL 3163.

Gastrointestinal MDL (MDL No. 3094)

The original litigation, this MDL focuses on severe digestive injuries such as gastroparesis, intestinal blockage and chronic vomiting. More than 3,300 lawsuits are pending as of March 2026. Plaintiffs allege manufacturers failed to warn that these drugs could significantly impair digestion.

Vision loss MDL (MDL No. 3163)

Vision loss claims were separated into their own MDL on December 15, 2025. This MDL focuses only on eye injuries. In particular, the lawsuits largely center on non-arteritic anterior ischemic optic neuropathy (NAION), sometimes called an “eye stroke.” This MDL is still in early stages.

Although anyone can experience adverse reactions, certain individuals may be more vulnerable to serious complications.

Potential risk factors include:

• Pre-existing gastrointestinal disorders
• Diabetes-related nerve damage affecting stomach function
• Kidney disease or dehydration risk
• Older age
• Use of medications that slow digestion
• Rapid dose escalation

Motley Rice attorneys have represented thousands of patients seriously hurt by dangerous prescription and over-the-counter drugs. We understand that as a patient or family member, what you know about your or a loved one’s medications and possible legal actions may be limited.

If you think a medication has harmed you or made you sick, our attorneys have the resources needed to thoroughly investigate and pursue justice for you and your family.

Read more about our medical drug litigation.

Disclaimer: Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor’s advice can result in injury or death. Mounjaro, Zepbound, Ozempic, Wegovy, Rybelsus and Saxenda remain approved by the U.S. Food and Drug Administration.